Adjusted hazard ratios hospitalization and death reduced with both treatments.
No significant reduction seen in percent of patients with urgent care or emergency department visits or hospitalization.
Molnupiravir and nirmatrelvir-ritonavir combination therapy should be considered for patients within 5 days of symptom onset.
Review and meta-analysis show improvements in functional exercise capacity vs standard of care.
New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.
No variation in risk for PCC seen based on number of vaccinations, but previous infection linked to reduced PCC risk.
Vaccination linked to reduced odds ratio of COVID-19-related emergency department or urgent care encounter, outpatient visits.
Similar immune response and no increase in rate of reactogenicity events seen with coadministration vs COVID-19 vaccine alone.
Findings seen for 50 most common questions about false information, myths, and false and true contraindications.